{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-066032","form_type":"8-K","ticker":"XENE","cik":"0001582313","company_name":"Xenon Pharmaceuticals Inc.","filed_at":"2023-11-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.634266+00:00","generated_at":"2026-06-07T21:28:19.997279+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Xenon reports Phase 2 XEN1101 MDD trial misses primary endpoint but hits secondary measures","bullets":["MADRS at week 6: placebo reduction 13.90; XEN1101 20 mg reduction 16.94 (p=0.135), not statistically significant.","HAM-D17 (p=0.042) and anhedonia SHAPS (p=0.046) secondary endpoints met statistical significance for 20 mg.","Early onset: MADRS at week 1 showed significance for 20 mg (p=0.047); CGI-I also significant (p=0.004).","XEN1101 well tolerated; no SAEs in active arms; common TEAEs: dizziness (17.9%), somnolence (10.7%), headache (8.9%).","Company exploring future MDD development; XEN1101 also in Phase 3 epilepsy with no titration required."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-066032","json":"https://secwatch.observer/filing/0000950170-23-066032.json","markdown":"https://secwatch.observer/filing/0000950170-23-066032.md","text":"https://secwatch.observer/filing/0000950170-23-066032.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1582313/000095017023066032/0000950170-23-066032-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1582313/000095017023066032/xene-20231127.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T21:28:19.997279+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}